Foundation for Therapeutic Advancement and Innovation with Psychedelics

Foundation for Therapeutic Advancement and Innovation with Psychedelics

TAIP advances science-based approaches to using psychedelics in contemporary therapeutic practices.

Mental health crisis

Mental health crisis

Mental health disorders are widely spread. According to the latest study by the National Institute of Health Development regarding mental health in Estonia around a quarter of the adults were diagnosed with a psychiatric disorder  between the period of 2016-2021. Unfortunately, many patients do not respond to commonly used treatment options. Mental health crisis has a detrimental effect on the quality of life for many people which can reduce healthspan and has a devastating impact on our healthcare systems. 

According to the 2018 report Health at a Glance: Europe 2018 conducted by OECD and the European Commission the total cost of mental disorders is estimated to impact the combined gross domestic product (GDP) of the United Kingdom and European Union  by 4% (ca 600 billion euros). The following report published in 2022 titled Health at a Glance: Europe 2022 highlights the severe impact of the COVID-19 pandemic on mental health, which has been especially notable in young people. As current treatment options have been unable to handle the scope of the mental health crisis, there is an urgent need for novel solutions.

Mental health disorders are widely spread. According to the latest study by the National Institute of Health Development regarding mental health in Estonia around a quarter of the adults were diagnosed with a psychiatric disorder  between the period of 2016-2021. Unfortunately, many patients do not respond to commonly used treatment options. Mental health crisis has a detrimental effect on the quality of life for many people which can reduce healthspan and has a devastating impact on our healthcare systems. 

According to the 2018 report Health at a Glance: Europe 2018 conducted by OECD and the European Commission the total cost of mental disorders is estimated to impact the combined gross domestic product (GDP) of the United Kingdom and European Union  by 4% (ca 600 billion euros). The following report published in 2022 titled Health at a Glance: Europe 2022 highlights the severe impact of the COVID-19 pandemic on mental health, which has been especially notable in young people. As current treatment options have been unable to handle the scope of the mental health crisis, there is an urgent need for novel solutions.

What are psychedelics?

What are psychedelics?

Psychedelics are a group of psychoactive substances that have a remarkably diverse effect on the consciousness experience. They can strongly affect senses, mood, thinking and emotions. Psychedelics have been used in several indigenous cultures for thousands of years, where their use has been related to sacred rituals and ceremonies. Scientific research into the effects of psychedelics on the human mind, however, has been conducted since the mid-twentieth century. Classical psychedelics include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD) and mescaline. Contemporary scientific literature also considers 3,4-methylenedioxymethamphetamine (MDMA) and ketamine as non-classical psychedelics.

Psychedelics are a group of psychoactive substances that have a remarkably diverse effect on the consciousness experience. They can strongly affect senses, mood, thinking and emotions. Psychedelics have been used in several indigenous cultures for thousands of years, where their use has been related to sacred rituals and ceremonies. Scientific research into the effects of psychedelics on the human mind, however, has been conducted since the mid-twentieth century. Classical psychedelics include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD) and mescaline. Contemporary scientific literature also considers 3,4-methylenedioxymethamphetamine (MDMA) and ketamine as non-classical psychedelics.

TAIP Foundation:
goal and vision

TAIP Foundation:
goal and vision

TAIP is dedicated to advancing scientific research and practical therapies with psychedelics.

We look to create and develop opportunities for psychedelic-assisted therapy in Estonia to alleviate the devastating consequences of the mental health crisis and improve public health and personal development. TAIP strives to build a safe and ethical legal framework for using psychedelic medicines based on rigorous research, international initiatives, educational activities and political counseling. We will include experts from healthcare, law, legislature and civic society to ensure a transparent and sustainable access to psychedelic-assisted therapy.

We envision a future where therapeutic advantages of psychedelics are accessible to patients and potential harms of the substances are minimised.

TAIP Foundation Management: Mari Salla and Oliver Berg. Photo: Siim Vahur

Our partners

Do you want to support the cause
or are you interested in co-operation? 

Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega

info@sataip.ee

Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega

info@sataip.ee

Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega

info@sataip.ee